Functionality of probiotics - potential for product development.

James Dekker, Michael Collett, Jaya Prasad, Pramod Gopal
{"title":"Functionality of probiotics - potential for product development.","authors":"James Dekker,&nbsp;Michael Collett,&nbsp;Jaya Prasad,&nbsp;Pramod Gopal","doi":"10.1159/000107196","DOIUrl":null,"url":null,"abstract":"<p><p>It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10 and DR20 brands, respectively) and by third parties (e.g. under the HOWARU brand by Danisco). While the 'gold standard' of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.</p>","PeriodicalId":55148,"journal":{"name":"Forum of Nutrition","volume":"60 ","pages":"196-208"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000107196","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000107196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peerreviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10 and DR20 brands, respectively) and by third parties (e.g. under the HOWARU brand by Danisco). While the 'gold standard' of proof of efficacy is a phase III clinical trial, ethical considerations as well as expense preclude the use of clinical trials as screening tools for probiotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift toward probiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
益生菌的功能-产品开发的潜力。
越来越多的消费者接受了活的乳酸菌在食用时确实对健康有好处。此外,人们也逐渐认识到,并非所有的益生菌都是一样的。现在的问题不再仅仅是在产品中提供足够数量的活菌;企业还必须提供每种菌株的有效性证明。上世纪90年代初,恒天然启动了一项开发专有益生菌菌株的计划,并最终将两种菌株——乳酸双歧杆菌HN019和鼠李糖乳杆菌HN001商业化。在过去十年中,恒天然针对这些菌株发表了大量经同行评审的报告,其中包括在动物和人体试验中显示安全性的研究,对鼠伤寒沙门氏菌和大肠杆菌O157:H7等病原体的保护作用,以实际剂量率调节人类和动物免疫标记物,以及在人体临床试验中的有效性。基于这项工作,HN019和HN001已被恒天然(分别以DR10和DR20品牌)和第三方(如丹尼斯克的HOWARU品牌)应用于几种功能食品中。虽然疗效证明的“黄金标准”是III期临床试验,但伦理考虑和费用排除了使用临床试验作为益生菌筛选工具的可能性。因此,必须使用生物标志物来识别具有益生菌效用的菌株,并定义现有益生菌菌株的不同积极健康益处。然而,由于大多数益生菌发挥其健康益处的机制尚不清楚,哪些生物标志物准确反映体内功效的问题仍未解决。随着最近的技术进步,以及针对特定条件的益生菌的转变,研究人员开始梳理益生菌是如何工作的,正是这些知识将为生物标志物的开发提供信息,并提高向市场提供安全有效的益生菌功能食品的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Metabolic imprinting in obesity. Do leptin and insulin signal adiposity? Leptin-signaling pathways and leptin resistance. Hypothalamic-brainstem circuits controlling eating. Brainstem integrative function in the central nervous system control of food intake.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1